<div class="headers"><div>Fig. 4 Impact of baseline psoriasis-associated itch severity on the response rate for C 90% improvement in Psoriasis Area and Severity Index from baseline at the end of the induction period (week 12) in patients with Itch Numeric Rating Scale C 4 at baseline (intent-to-treat population). Pooled data from UNCOVER-2 and 3; NRI; treatment p \ 0.001, baseline Itch NRS category p = 0.021, treatment 9 baseline Itch NRS category (p = 0.148). Itch NRS 4–6, 7–8, and 9–10 indicate the Itch NRS score at baseline. ETN etanercept, IXE ixekizumab, NRI nonre-sponder imputation, NRS Numeric Rating Scale, PASI Psoriasis Area and Severity Index, PASI 90 C 90% improvement in PASI from baseline, PBO placebo, Q2W every 2 weeks. *p \ 0.001 versus ETN and PBO</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; border-bottom: 2px solid grey; text-align: left;'><p style="" class="">Fig. 4 Impact of baseline psoriasis-associated itch severity on the response rate for C 90% improvement in Psoriasis Area and Severity Index from baseline at the end of the induction period (week 12) in patients with Itch Numeric Rating Scale C 4 at baseline (intent-to-treat population). Pooled data from UNCOVER-2 and 3; NRI; treatment p \ 0.001, baseline Itch NRS category p = 0.021, treatment 9 baseline Itch NRS category (p = 0.148). Itch NRS 4–6, 7–8, and 9–10 indicate the Itch NRS score at baseline. ETN etanercept, IXE ixekizumab, NRI nonre-sponder imputation, NRS Numeric Rating Scale, PASI Psoriasis Area and Severity Index, PASI 90 C 90% improvement in PASI from baseline, PBO placebo, Q2W every 2 weeks. *p \ 0.001 versus ETN and PBO</p></td>
</tr>
</tbody>
</table>
